Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

G J Ossenkoppele, D A Breems, G Stuessi, Y van Norden, M Bargetzi, B J Biemond, P A von dem Borne, Y Chalandon, J Cloos, D Deeren, M Fehr, B Gjertsen, C Graux, G Huls, J J J W Janssen, A Jaspers, M Jongen-Lavrencic, E de Jongh, S K Klein, M van der KliftM van Marwijk Kooy, J Maertens, L Michaux, M W M van der Poel, A van Rhenen, L Tick, P Valk, M C Vekemans, W J F M van der Velden, O de Weerdt, T Pabst, M Manz, B Löwenberg, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Search results

  • 2020

    Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

    Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., von dem Borne, P. A., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., van der Klift, M., & 26 othersKooy, M. V., Maertens, J., Micheaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., Lowenberg, B., Havelange, V., Moors, I., van Obberg, F., Maertens, J. A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Passweg, J., Heim, D., Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) & Swiss Group for Clinical Cancer Research (SAKK), 1 Jul 2020, In: Leukemia. 34, 7, p. 1751-1759 9 p.

    Research output: Contribution to journal › Article › Academic › peer-review